Cargando…
PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429310/ http://dx.doi.org/10.1097/01.HS9.0000851256.24064.82 |
| _version_ | 1784779400938520576 |
|---|---|
| author | De La Fuente, A. Peñalver, F. J. Herrera, P. Cordoba, R. Martinez Chamorro, C. Olave, M. T. Jarque, I. Navarro, M. B. Estévez, M. |
| author_facet | De La Fuente, A. Peñalver, F. J. Herrera, P. Cordoba, R. Martinez Chamorro, C. Olave, M. T. Jarque, I. Navarro, M. B. Estévez, M. |
| author_sort | De La Fuente, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429310 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94293102022-08-31 PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2 De La Fuente, A. Peñalver, F. J. Herrera, P. Cordoba, R. Martinez Chamorro, C. Olave, M. T. Jarque, I. Navarro, M. B. Estévez, M. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429310/ http://dx.doi.org/10.1097/01.HS9.0000851256.24064.82 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only De La Fuente, A. Peñalver, F. J. Herrera, P. Cordoba, R. Martinez Chamorro, C. Olave, M. T. Jarque, I. Navarro, M. B. Estévez, M. PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2 |
| title | PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2 |
| title_full | PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2 |
| title_fullStr | PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2 |
| title_full_unstemmed | PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2 |
| title_short | PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2 |
| title_sort | pb2106: reduction of methotrexate (mtx) levels after glucarpidase in patients with diffuse large b-cell lymphoma (dlbcl) at risk of central nervous system (cns) involvement who receive hdmtx: phase 2 |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429310/ http://dx.doi.org/10.1097/01.HS9.0000851256.24064.82 |
| work_keys_str_mv | AT delafuentea pb2106reductionofmethotrexatemtxlevelsafterglucarpidaseinpatientswithdiffuselargebcelllymphomadlbclatriskofcentralnervoussystemcnsinvolvementwhoreceivehdmtxphase2 AT penalverfj pb2106reductionofmethotrexatemtxlevelsafterglucarpidaseinpatientswithdiffuselargebcelllymphomadlbclatriskofcentralnervoussystemcnsinvolvementwhoreceivehdmtxphase2 AT herrerap pb2106reductionofmethotrexatemtxlevelsafterglucarpidaseinpatientswithdiffuselargebcelllymphomadlbclatriskofcentralnervoussystemcnsinvolvementwhoreceivehdmtxphase2 AT cordobar pb2106reductionofmethotrexatemtxlevelsafterglucarpidaseinpatientswithdiffuselargebcelllymphomadlbclatriskofcentralnervoussystemcnsinvolvementwhoreceivehdmtxphase2 AT martinezchamorroc pb2106reductionofmethotrexatemtxlevelsafterglucarpidaseinpatientswithdiffuselargebcelllymphomadlbclatriskofcentralnervoussystemcnsinvolvementwhoreceivehdmtxphase2 AT olavemt pb2106reductionofmethotrexatemtxlevelsafterglucarpidaseinpatientswithdiffuselargebcelllymphomadlbclatriskofcentralnervoussystemcnsinvolvementwhoreceivehdmtxphase2 AT jarquei pb2106reductionofmethotrexatemtxlevelsafterglucarpidaseinpatientswithdiffuselargebcelllymphomadlbclatriskofcentralnervoussystemcnsinvolvementwhoreceivehdmtxphase2 AT navarromb pb2106reductionofmethotrexatemtxlevelsafterglucarpidaseinpatientswithdiffuselargebcelllymphomadlbclatriskofcentralnervoussystemcnsinvolvementwhoreceivehdmtxphase2 AT estevezm pb2106reductionofmethotrexatemtxlevelsafterglucarpidaseinpatientswithdiffuselargebcelllymphomadlbclatriskofcentralnervoussystemcnsinvolvementwhoreceivehdmtxphase2 |